New Drug Extends Hope for Advanced Prostate Cancer Patients

For men with advanced prostate cancer that no longer responds to standard treatments, a new drug is offering extra time and renewed hope.

Researchers at the Medical University of South Carolina and Emory University tested whether an experimental drug called opaganib could extend the effectiveness of existing hormone therapies. The results, published in Cancer Medicine, show real promise for patients facing limited options.

The study focused on 66 men with metastatic castration-resistant prostate cancer, the most aggressive form of the disease. Their cancer had already spread and stopped responding to standard hormone-blocking drugs like abiraterone and enzalutamide.

While only 9 to 15 percent of patients met the study's primary goal of disease control at 16 weeks, many showed clear biological signs of improvement. PSA levels dropped, and the disease stabilized, allowing patients to stay on gentler treatments longer instead of moving to harsh chemotherapy.

"Even though it's a small percentage, those are real patients," said Dr. Besim Ogretmen, study co-author and associate director of basic science at Hollings Cancer Center. "We're talking about people who are benefiting from this treatment when others have not worked."

What makes opaganib different is how it works. Instead of targeting hormones, it blocks a pathway cells use to manage fats, which can help cancer grow and resist treatment. Few drugs currently target this pathway, making this approach genuinely novel.

The drug also proved manageable for most patients. Side effects were typically mild to moderate, and when serious issues arose, reducing the dose usually helped.

The Ripple Effect

The real breakthrough may be what comes next. Researchers are now analyzing blood samples to identify biomarkers that predict which patients will respond best to the treatment. This precision medicine approach could transform care by matching the right therapy to the right person at the right time.

The drug itself has deep roots at MUSC, where it was developed from foundational research by Dr. Charles Smith and advanced through years of laboratory work before reaching patients. This journey from lab bench to bedside shows how sustained investment in cancer research creates real options for people when they need them most.

Dr. Omer Kucuk, oncologist at Emory's Winship Cancer Center, emphasized the importance of exploring new pathways. "After standard therapies fail, there are limited precise options for individualized treatment," he said.

The collaboration between MUSC and Emory, partially supported by the National Cancer Institute, demonstrates how institutions working together can accelerate progress for patients facing the toughest diagnoses.

This small but meaningful step forward means more men with advanced prostate cancer have reason to hope for more time with their families.